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Abstract 
Iron is an abundant transition metal that is essential for life, being associated to many enzyme and 
oxygen carrier proteins involved in a variety of fundamental cellular processes. At the same time 
the metal is potentially toxic due to its capacity to engage in the catalytic production of noxious 
reactive oxygen species. The control of iron availability in the cells is largely dependent on ferritins, 
ubiquitous proteins with storage and detoxification capacity. In mammals, cytosolic ferritins are 
composed of two types of subunits, the H and the L chain, assembled to form a 24-mer spherical 
cage. Ferritin is present also in mitochondria, in the form of a complex with 24 identical chains. 
Even though the proteins have been known for a long time, their study is a very active and 
interesting field yet. In this review we will focus our attention to mammalian cytosolic and 
mitochondrial ferritins, describing the most recent advancement regarding their storage and anti-
oxidant function, the effects of their genetic mutations in human pathology, and also the possible 
involvement in non-iron related activities. We will also discuss  recent evidence connecting ferritins 
and the toxicity of iron in a set of neurodegenerative disorder characterized by focal cerebral 
siderosis.  
 
Introduction 
The adaptation of life to an oxic environment  required the development of mechanisms to deal with 
the transformation of the water soluble ferrous ion (Fe
2+
) to the insoluble ferric ion (Fe
3+
) and with 
the concomitant generation of dangerous reactive oxygen species (ROS). The ferritin molecules 
represent an important and ancient mean developed by organisms in the three domains of life to 
safely handle the necessary, yet potentially toxic metal. Their ability to detoxify and store the metal 
through safe oxidation processes protects the cells  from undue iron-dependent redox  chemistry, 
while a controlled release of the metal guarantees its availability for different and essential 
enzymatic reactions.  Storage and detoxification of iron represent the main functions of these 
molecules, and much work has been done to understand the chemical and molecular details of this 
processes in the different types of ferritins, the classical ones, the heme-containing bacterioferritins 
and the smaller docecameric Dps proteins. These findings have been described in various excellent 
reviews of the recent years (Arosio and Levi 2010; Bou-Abdallah 2010; Theil 2013), but the interest 
in ferritin is not fading and new interesting data are continuously appearing. In this review we focus 
our attention to the mammalian ferritins and their possible involvement in the perturbation of iron 
homeostasis often observed in neurodegenerative disorders.  Interestingly, there is mounting 
evidence that mammalian ferritins can also exert functions not related to the iron storage-
detoxification processes. We will discuss this novel and unexpected  activities and their potential 
significance for human physiopathology.   
 
Mammalian ferritin structure   
In mammalian ferritins, 24 subunits assemble to form a hollow symmetrical protein with a 
molecular weight of about 480 kDa; the multimer is a shell with an outer diameter of 12 nm limiting 
a 8-nm diameter cavity that can accommodate up to 4500 iron atoms. Structural analysis shows that 
the protein cage is composed by dimers arranged with a 4,3,2 symmetry with 8 hydrophilic pores at 
the connection of three subunits, and 6 hydrophobic channels at the connection of four subunits 
(figure 1). In each subunit most of the amino acid residues are within 5 -helix secondary 
structures, identified as A, B, C, D and E and a long loop between B and C helices. Helixes A to D 
constitute the common and roughly cylindrical four-helical bundle structural motif (Punta et al. 
2012) (figure 2) characterizing the many proteins belonging to the Ferritin-like superfamily 
(Andrews 2010), whereas the 5
th
 helix E stems from one end of the bundle with an angle of about 
60°. The helixes A and C, together with the unstructured NH2-terminus and the long B-C loop are 
exposed to the outside of the protein, whereas the B and D helices are buried inside it.  Three 
different type of monomer are in mammalian cells: the H (FtH, heart/heavy, ~21 kDa) and L (FtL, 
liver/light, ~19 kDa) monomers are constituents of the ubiquitous and most abundant cytosolic 
ferritins, while the mitochondrial subunit (FtMt, ~21 kDa) is found exclusively in the mitochondrial 
ferritin. RNAs potentially coding for other types of ferritin subunits have been identified (FtH-L17), 
but no protein products have been associated with them so far (Wang et al. 2001). The three 
monomers show high level of homology but only FtH and FtMt conserve the amino acids required 
for the formation of a di-iron ferroxidase center, buried inside the -helix bundle, that catalyzes the 
oxidation from ferrous to ferric iron necessary for iron deposition in the cavity (figure 3A and B) 
(Harrison and Arosio 1996). On the contrary, the L-subunit presents a nucleation site, a cluster of 
cavity-exposed carboxyl residues that can bind Fe(III) ions, that facilitates iron nucleation and 
hydrolysis, the late steps of core formation (Santambrogio et al. 1996). Thus, the presence of both 
chains in the cytosolic ferritin is associated with improved storage functionality. The assembly of 
the H and L subunits into the 24-mer cytosolic shell produces a variety of different molecules 
(isoferritins) (Drysdale et al. 1977) differing for the relative abundance of each monomer. This 
depends on the type of tissue and also on the pathophysiological conditions. Tissues with a main 
storage function (liver, spleen) contain L-rich (up to 90%) ferritins, that are more stable and may 
contain more iron, while those with high iron oxidation activity (heart, brain) favor the H-rich 
ferritins, with a significant anti-oxidant activity (Wagstaff et al. 1978; Harrison and Arosio 1996); 
since the L and H ferritin gene transcription is modulated by different stimuli (see below), the 
composition of the multimeric protein may also be affected by factors such as oxidative stress, 
inflammation and hypoxia. In contrast to the cytosolic ferritin, the mitochondrial ferritin is a 24-mer 
homopolymer: the mitochondrial subunit is encoded by a distinct, nuclear and intronless gene; its 
protein products has a N-terminal targeting sequence that drives the protein to mitochondria, where 
it is processed to a mature peptide with a size similar to that of the H and L peptides (Drysdale et 
al.). Ferritins are found also in other cellular compartments (lysosomes and nucleus), in 
extracellular  fluids and in the blood. Serum ferritin is predominantly made by L subunits (Cazzola 
et al. 1985; Santambrogio et al. 1987) and is a significant clinical parameter for the diagnosis and 
monitoring of iron overload or deficiency. Different reviews dealt with this topic (Wang et al. 2010; 
Ferraro et al. 2012) that will be not further considered in this manuscript.    
 
Iron flux in and out the ferritin cage. 
The 24 subunits come together in a three-dimensional structure that is designed for the dynamic 
storage of iron; extensive intra- and inter-subunits helix-helix interactions give rise to a very stable 
protein (it resists up to 80C°, 6M guanidine and pH 3-10) (Martsev et al. 1998) yet maintaining 
sufficient flexibility to allow the flux of iron and other small molecules in and out of its shell (Liu 
and Theil 2005). The protein actually shows eight narrow hydrophilic channels around the 3-fold 
symmetry axes and six hydrophobic channels around the 4-fold axes, all with a diameter of about 
0.4 nm (figure 1). Compelling in vitro evidence suggests that the iron entry route is represented by 
the hydrophilic channels (Chasteen 1998; Yang et al. 2000) whereas the hydrophobic ones seem to 
be involved in the diffusion of oxygen and hydrogen peroxide (Liu and Theil 2005). The transfer of 
iron inside the cavity has been extensively studied in vitro; in the accepted mechanism  Fe(II) binds 
to ferritin via carboxylate side chains that line the 3-fold axes pores and then moves to the 
ferroxidase center. Here two iron atoms bind to the catalytic site where oxidation occurs in the 
presence of O2 and with the generation of hydrogen peroxide. The latter is consumed for iron 
oxidation in neighboring ferroxidase centers (Zhao et al. 2003). This couples the storage activity to 
an anti-oxidant reaction that consumes the reagents of the Fenton reaction (figure 3C). The oxidized 
iron atoms move to the cavity, hydrolyze and form the mineral core (Bou-Abdallah et al. 2002). The 
iron core offers sites that facilitate iron oxidation, in competition with the ferroxidase center, 
allowing the direct oxidation and deposition of the metal on the mineral surface (Chasteen and 
Harrison 1999; Bou-Abdallah 2010). The structure of native and reconstituted iron cores has been 
studied by various physical and chemical approaches and different models have been proposed. 
Recent analysis performed with nanoanalysis techniques (Quintana and Gutiérrez 2010) indicate 
that ferritin cores have a polyphasic structure,  with two or three crystalline phases (ferrihydrite, 
magnetite and hematite) co-existing inside the cavity (Cowley et al. 2000; Gálvez et al. 2008). Iron 
loading mechanisms inside the cells probably reflect those studied in vitro, even though higher level 
of complexity and regulation may be present; in particular the interaction and loading of ferritins 
with iron may be enhanced in vivo by iron chaperones such as the PCBPs that can interact with 
ferritin with nanomolar affinity and may deliver iron directly at the hydrophilic pores (Shi et al. 
2008; Leidgens et al. 2013). This activity is not specific to ferritin since PCBP1 and PCBP2 also 
facilitate iron delivery to enzymes with mononuclear and dinuclear iron centers, deoxyhypusine 
hydroxylase and prolyl and asparagyl hydroxylases respectively (Nandal et al. 2011; Frey et al. 
2014) and PCBP2 can mediate cytosolic iron distribution by interacting with the membrane 
transporters DMT1 and Ferroportin (Yanatori et al. 2014). Further studies are needed to understand 
the role of these ubiquitous RNA/DNA binding proteins in the maintenance of iron homeostasis. 
The iron stored in the ferritin cavity is readily available to cellular demand. The mechanisms 
governing the exit of the metal from the protein deposit are not clear yet and the physiological 
relevance of the data obtained in vitro is still debated. The 3-fold channels seem to be the main 
route of both iron entry and exit from the protein shell (Wardeska et al. 1986), with the negatively 
charged amino acids paving their surface playing a fundamental role in determining the types of 
ions and molecules that can access inside the cage (Takahashi and Kuyucak 2003). In vitro, the 
removal of iron is efficient in the presence of reducing agents and chelators, even those larger than 
the diameter of the channel (Jones et al. 1978; Watt et al. 1988); this could be explained by a direct 
transfer of electrons from the exterior reductants to the inner mineral core through the 2 nm ferritin 
wall. In bacterial ferritin the transfer seems to be facilitated by the heme groups in proximity to the 
mineral core (Richards et al. 1996), but it was described also in animal ferritin heteropolymers with 
H and L subunits (Johnson et al. 1999). Also a significant flexibility of the channels has to be taken 
into account, thus considering that they may behaves similarly to the gated pores that regulate 
molecules diffusion through the cell membranes (Theil et al. 2008). Increasing temperature, 
physiological concentration of chaotropic reagents or site-directed mutagenesis of specific residues 
of tadpole M-ferritin (Leu-110, Arg-72 an d Asp-122) have been shown to dramatically increase the 
in vitro rate of ferritin iron release by altering the stability of the 3-fold channels. Furthermore, the 
screening of a combinatorial library brought to the identification of peptides capable of binding to 
ferritin, opening or closing the pores and thus modulating the rate of iron release (Liu et al. 2007). 
This finding led to the speculative proposal of regulatory molecules controlling the breathing of the 
gated pores in vivo. Of note, significant reduction in iron retention could be observed also when 
ferritins with a perturbed 4-fold channels structure were expressed in HeLa cells (Cozzi et al. 2006; 
Cozzi et al. 2010). Despite the detailed in vitro studies and the proposed models, the in vivo 
physiological relevance of direct iron release from ferritins is far from clear. In order to be 
mobilized iron must be reduced to soluble Fe(II) ions, but the physiological reducing machinery has 
not been identified, and, more important, if the mechanism is not tightly regulated it probably 
involves one-electron transfer process that is  potentially toxic for the generation of free radicals.  
This means that ferritin iron under certain conditions may exert pro-oxidant activity. In fact this has 
been observed in some reports. The incubation of ferritin with H2O2 (Liu and Hu 2009), salsolinol 
(Kang 2009) or methylglyoxal and lysine (An and Kang 2013) caused oxidative DNA damage, and 
this was prevented by iron chelators. Furthermore the presence of mutant L ferritin with a perturbed 
COOH-terminal structure as observed in neuroferritinopathy patients  leads to excess LIP and ROS 
generation (see also  below) (Levi and Finazzi 2014). It is thus possible that, in specific chemical or 
genetic conditions, iron release from ferritin may be toxic to cells and tissues and contribute to the 
pathology. 
In vivo, the major way to mobilize iron from its cellular storage is via the degradation of the ferritin 
cage itself (Linder 2013), as shown in cells exposed to restriction of iron availability (Truty et al. 
2001). The involvement of lysosomes in ferritin degradation and the concomitant iron release has 
been shown in different cell lines exposed to iron chelating agents (particularly deferoxamine 
(DFO) or overexpression of FtMt) (Kidane et al. 2006; Zhang et al. 2010), bacterial infection 
(Larson et al. 2004), and ferroportin activation (Asano et al. 2011). Lysosomal inhibitors, but not 
proteasomal inhibitors, could halt the degradation, induce ferritin accumulation in the organelles 
and block iron release. Very recently a quantitative proteomic study identified the Nuclear Receptor 
Coactivator 4 (NCOA4) as a cargo receptor mediating ferritin delivery to the autophagosome 
(Mancias et al. 2014), thus indicating a possible new level of regulation of cellular iron 
homeostasis. The intra-lysosomal degradation of ferritin has the advantage to shield the other 
cellular components by the potential toxicity of iron allowing a controlled release of the metal to the 
cytosol, where it increases LIP  level (Asano et al. 2011) and induces ferritin synthesis (Garner et al. 
1998). Nonetheless there are reports showing that ferritin, and particularly apo- and iron poor-
ferritin, can be degraded also by the proteasome. Indeed, oxidized ferritin is a target of proteasome 
degradation (Rudeck et al. 2000) and lactacystin, a proteasome inhibitors, can increase ferritin 
stability in iron replete cells (Zhang et al. 2010). The overexpression of ferroportin in HEK293 cells 
in iron replete conditions induced ferritin loss (but apparently not iron release) via ubiquitination 
and proteasome degradation (De Domenico et al. 2006). Similar results were obtained exposing the 
same cells to deferasirox and deferiprone, chelating agents  targeted to the cytosol, whereas DFO 
induced the lysosomal pathway (De Domenico et al. 2009). Interestingly, the expression of 
neuroferritinopathy-related L ferritin mutants in HeLa cells was associated with an increased 
proteasomal degradation of ferritin (Cozzi et al. 2006). Altogether both the lysosomal and the 
proteasomal pathways of degradation seem to be recruited to mobilize iron from ferritin, probably 
depending on the cell type and the cellular conditions. 
 
Regulation of ferritin expression 
 
The main functions of the cytosolic ferritins are the reversible storage of iron and the prevention of 
iron-mediated oxidative stress. This is supported by the stimuli and mechanisms involved in 
controlling their expression, mostly related to iron and stress, both at the transcriptional and  the 
translational levels (Torti and Torti 2002; Theil 2007). Transcriptional mechanisms are involved in 
determining the tissue specific H to L ratio and are only modestly elicited by chronic iron 
supplementation (Cairo et al. 1985). However heme was shown to be a strong inducer in some 
cellular systems: it acts by removing Bach1 repressor  and permitting the binding of the 
transcription factor Nrf2 (Hintze and Theil 2006; Hintze et al. 2007). Also oxidative stress  induced 
a significant increase (up to 80 fold)  in ferritin mRNA (Torti and Torti 2002; Hintze and Theil 
2005). A combination of different repressor (Bach1 and ATF1) (Iwasaki et al. 2007; Hintze et al. 
2007) and  activators (Nrf2, JunD) (Iwasaki et al. 2006; MacKenzie et al. 2008) are involved in the 
recognition and binding of the Antioxidant Response Elements (ARE) in the promoter region of 
mouse ferritin H and L genes, modulating their expression  in response to oxidative stimuli. 
Different signaling cascades may enroll such DNA binding factors; for instance, the activation of 
PI3-kinase was required for ferritin H induction by oxidative agents in Jurkat cells (Sakamoto et al. 
2009); in the same cell type resveratrol, a molecule with antioxidant properties, induced ferritin H 
transcription via the recruitment of AMP-activated kinase (Iwasaki et al. 2013). The induction of 
ferritin for detoxification purposes has been observed also in other condition of cellular stress: 
genotoxic stimuli (doxorubicin and etoposide) were shown to increase ferritin H transcription 
through the activation of the Homeodomain Interacting Protein Kinase 2 (HIPK2) and consequent  
removal of the ATF1 repressor in MEF cells (Hailemariam et al. 2010); similarly inflammatory 
stimuli and particularly TNF- and Interleukin-1 and -6, can induce ferritin expression, and 
particularly the H chain (Torti and Torti 2002). The increased capacity to sequester iron is an 
efficient protective mechanism against cellular stress, as shown by the block of the TNF-/JNK 
mediated apoptosis obtained through the NF-kb-dependent activation of ferritin transcription (Pham 
et al. 2004). Other pathways of regulation suggest the possible association of ferritin with 
alternative, cell specific functions (see below); adiponectin can increase ferritin expression in 
primary skeletal muscle cells by recruitment of NF-kb (Ikegami et al. 2009) while in neurons a 
transcription-dependent increase of ferritin H is observed upon the activation of -opiod receptors 
(Sengupta et al. 2009). A strong post-transcriptional regulation of ferritin is superimposed to the 
transcriptional one to guarantee rapid adaptations to changes in iron levels and oxidative stress. This 
mechanism represents an elegant example of coordinated cytosolic regulation of gene expression 
(Hentze et al. 1989). It is based on the action of two Iron Responsive Proteins, IRP1 and IRP2. 
They can bind with high affinity to an hairpin structure, the Iron Responsive Element (IRE), located 
in the 5’-UTR of ferritin H and L mRNAs (Theil 2007). The binding is modulated by cellular iron 
and redox status: when iron levels are low, both IRP1 and IRP2 sit onto the IREs of H and L (figure 
4) mRNAs, thus blocking their translation; when iron is available IRP2 is degraded by the 
proteasome (Guo et al. 1995), while IRP1 binds to a 4Fe-4S cluster and covert to the cytosolic 
aconitase enzyme (Rouault and Tong 2005). Under oxidative condition the iron sulfur cluster of 
aconitase can be destroyed, thus inducing the switch to IRP1 (Pantopoulos et al. 1997), while the 
oxidation of cysteines in IRP2 promotes its degradation (Zumbrennen et al. 2009). Under reducing 
condition there is no urgent need to sequester iron and ferritin synthesis can be repressed, while the 
opposite happens in the presence of an oxidative environment. No definitive explanation exist yet 
for the existence of two IRPs with different type of regulation, even though IRP2 seems to be the 
only functional  IRE ligand at low oxygen tension (Hanson et al. 2003). 
 
Cytosolic ferritin, iron and ROS production: a delicate balance. 
 
The fundamental role of ferritin as a storage and antioxidant agent is documented by a significant 
amount of data generated both in vitro and in vivo and related to different pathophysiological 
conditions (Arosio and Levi 2010). The overexpression of ferritin H in HeLa (Cozzi et al. 2000) and 
erythroleukemia cells (Epsztejn et al. 1999) resulted in decreased iron and ROS generation, 
increased resistance to oxidative stress and prevention of TNF- induced apoptosis (Cozzi et al. 
2003). The overexpression of H mutants lacking the ferroxidase activity or of ferritin L did not 
induce the same phenotype, while the downregulation of ferritin H by specific siRNA had opposite 
effects. These results confirm the determinant role of ferritin H for the detoxification activity, and 
suggest that a correct balance in the expression of ferritin subunits may be similarly important. We 
may predict that abnormal low levels of ferritin H can be detrimental, as it occurs in the brain of 
mice with the deletion of a ferritin H allele that show   perturbation of iron and redox balance 
(Thompson et al. 2003), but also an excess of ferritin H may perturb iron homeostasis and cause a 
pro-oxidant condition, in the long run.  An interesting example of this was the finding that the 
overexpression of ferritin H in the substantia nigra of mice protected young mice from the noxious 
action of MPTP, but had opposite results in older mice (Kaur et al. 2003; Kaur et al. 2009). The 
balance can be altered in defects of FtL, as it occurred in a subject homozygous for enabling loss of 
function mutation of the FtL gene. The fibroblasts and reprogrammed neurons from the subject 
showed a reduced cellular iron availability associated with reduced catalase and SOD1 expression 
and with increased oxidative damage (Cozzi et al. 2013). So a correct balance of H and L subunits 
seems to be important for the proper dynamic equilibrium of cytosolic iron storage and availability. 
The in vitro data are confirmed and extended by analysis in vivo. The deletion of ferritin H in mice 
is embryonic lethal (Ferreira et al. 2000), while its conditional deletion in the adult mice led to a 
dramatic decrease in iron stores and a high sensitivity to iron excess and oxidative damage, both in 
the mice and the derived MEFs (Darshan et al. 2009). Mice with different FtH tissue-selective 
deletions were generated by mating animals with floxed FTH gene and transgenic mice with cre-
recombinase under different promoters. The specific deletion of the gene in the kidney proximal 
tube was associated with decreased ferroportin levels and higher mortality upon induction of acute 
kidney injury (Zarjou et al. 2013). Increased LIP and ROS and mitochondrial depolarization were 
observed in lymphocytes form mice with Mx-Cre mediated conditional deletion (Vanoaica et al. 
2014); the survival and maturation of B-cells exposed to B-cell activating factor was reduced and 
partially rescued by iron chelation with deferiprone. Interestingly, the deletion of the gene in the 
intestine was associated with increased  iron body stores and related parameters (transferrin 
saturation, hepatic hepcidin mRNA level); nonetheless intestinal iron absorption was twofold higher 
than in wild type animals, thus suggesting a role for ferritin in the “mucosal block”, the balance 
between iron retained in the cells and the ones to be transferred through basolateral membrane 
(Vanoaica et al. 2010). The storage and anti-oxidant action of cytosolic ferritin has been shown to 
exert a strong protective effect in different in vivo models of cellular/organ stress. The 
ischemia/reperfusion injury is associated to many pathological conditions and protection against it 
is an important issue in modern medicine. It has been shown that exposure of the organ to a minor 
ischemic stress (ischemic preconditioning, IPC) before the overt ischemia/reperfusion has beneficial 
effects, with reduction of infarct size and acceleration of the recovery of the heart (Yang et al. 
2010). The strong induction of ferritin was found to have a major role in the IPC protection 
(Chevion et al. 2008). The induction was attributed to a rapid burst of free iron induced by a fast 
degradation of ferritin itself; this leads to apoferritin synthesis with consequent reduction of free 
iron and of the ROS production associated with the reperfusion process (Bulvik et al. 2012). Similar 
results have been obtained also in the retina (Obolensky et al. 2008) and in the hypothermic 
preconditioning of endothelial cells (Zieger and Gupta 2009). A protective effect from the pro-
oxidant action of heme has been shown in a mouse model of sickle cell anemia, where the 
overexpression of FtH, but not of FtL or of a mutated FtH without ferroxidase activity, significantly 
reduced the vascular stasis elicited by infusion of haemoglobin (Vercellotti et al. 2014). Data 
obtained both in mice and humans documented that iron sequestration by FtH can be crucial for the 
development of tolerance to malaria. The infection by Plasmodium was associated with the 
activation of the pro-apoptotic c-Jun N-terminal kinase (JNK), that, in turns, inhibited ferritin 
expression and promoted tissue iron overload and damage.  When FtH (in mice) or ferritin (in 
humans) was over-expressed,  it sequestered free iron and attenuated ROS production and JNK 
induction; this led to limitation of tissue damage, regardless of iron overload and pathogen burden 
(Gozzelino et al. 2012). 
Mitochondrial ferritin. 
Recently a mitochondrial ferritin (FtMt) has been identified (Levi et al. 2001). It is encoded by an 
intronless gene at human chromosome 5q23.1. It is synthesized as a precursor with a NH2-terminal 
stretch of charged amino acids that targets the peptide to the mitochondria; here a proteolytic 
processing generates the mature peptide, very similar to the cytosolic H chain, for sequence, 
structure and presence of a ferroxidase center (Langlois d’Estaintot et al. 2004; Levi and Arosio 
2004).  In fact the recombinant mature protein incorporates iron in vitro as efficiently as 
recombinant FtH (Bou-Abdallah et al. 2005). Contrary to the ubiquitous cytosolic ferritin, MtFt 
expression is limited to a few organs and cell types: in mice and humans the highest levels are 
found in testis, an particularly in spermatozoa, but mRNA and protein can be detected also in 
neurons of the brain and spinal cord, in the heart, kidney and pancreatic islet of Langherans 
(Santambrogio et al. 2007; Snyder et al. 2009; Wang et al. 2011). Since the mRNA lacks an IRE 
hairpin structure its expression is not regulated by iron at post-translational level and the protein is 
absent in iron storage organs, such as the liver and spleen. When overexpressed in cell lines, the 
protein causes a shift of cellular iron to mitochondria, with consequent iron deficiency in the cytosol 
(low ferritin and high TfR) and iron accumulation in the organelles (Corsi et al. 2002; Nie et al. 
2005; Wu et al. 2013). This suggests that FtMt can cooperate with cytosolic ferritin in the 
maintenance of  intracellular iron balance. It was also suggested that the main function of FtMt is 
the control of local iron availability of ROS production in mitochondria, particularly in cells with 
high metabolic rate. The expression of FtMt protected HeLa cells from different types of oxidative 
damage (Campanella et al. 2009) and reverted the perturbation of iron homeostasis induced by 
exposure to doxorubicin (Cocco et al. 2013). The expression of  FtMt was also shown to rescue the 
phenotype associated with frataxin deficiency, in yeast and mammalian cells (Campanella et al. 
2009) and partially also in fibroblasts form Friedrich Ataxia patients (Campanella et al. 2009), 
preventing ROS generation and mitochondrial iron loading, restoring the respiratory efficiency and 
preserving mitochondrial DNA integrity. When overexpressed in neuroblastoma SH-SY5Y cells, it 
protected the cells form the noxious activity of 6-OHDA (Shi et al. 2010) and also of -35 
peptide (Wu et al. 2013); in both cases ROS production and apoptosis induced by the toxic stimuli 
were significantly attenuated.  Supporting evidence for these antioxidant role come also from in 
vivo experiments. Mice lacking the gene are viable and have normal life span in normal condition 
(Bartnikas et al. 2010), but when exposed to doxorubicin they showed enhanced mortality with 
mitochondrial damage, fibril disorganization and signs of oxidative damage in the heart 
(Maccarinelli et al. 2014). Interestingly the down-regulation of FtMt expression in the hippocampus 
of rats obtained by injection of specific  siRNA molecules was associated with increased apoptosis 
and the exposure of animal to A25-35 peptide aggravated the phenotype with more intense 
oxidative damage (Wu et al. 2013); whether this effects in the animals were linked to alteration of 
iron handling was not shown. Some aspects of the role played by FtMt and iron balance in 
mitochondria and cells remain poorly understood and expect further comprehension. For instance, 
FtMt and mitochondrial iron deposits are found at highest levels in the ringed sideroblasts of 
Sideroblastic Anemia (SA, OMIM 300751) (Cazzola et al. 2003). It was initially thought that FtMt 
was a protective response to mitochondrial iron loading, but it was found that the enhanced 
expression of FtMt preceded iron accumulation, already at very early stages of erythroid 
differentiation and before signs of iron deposition (Della Porta et al. 2006). The understanding of 
such phenotype requires a deeper description of the mechanisms regulating the expression of the 
protein, that are almost completely unraveled. 
 
Ferritin mutations in genetic disorders. 
 
The crucial role of ferritin in the maintenance of iron balance is also confirmed by the analysis of 
the pathogenesis of different human disorders associated with perturbation of iron homeostasis. The 
most paradigmatic example is Neuroferritinopathy (OMIM, 606159), an autosomal dominant 
neurodegenerative disorder due to mutations in the FtL gene and mainly characterized by 
extrapyramidal symptoms (McNeill and Chinnery 2012; Levi and Finazzi 2014). Magnetic 
resonance imaging reveals signs of cerebral iron accumulation, particularly in the basal ganglia 
(Crompton et al.), and the histopathology confirmed the iron accumulation together with the 
presence of ferritin aggregates, with a nuclear or cytosolic localization, in neurons and glial cells; 
serum ferritin is often decreased (McNeill and Chinnery 2012). Different type of sequence 
variations have been found in patients (figure 5), all of them, but one, are nucleotide insertions in 
exon 4 of the FtL gene and alter the C-terminus of the FtL protein. Mice expressing high level of a 
human FtL mutant  (c.498-499dup) were described to recapitulate the human phenotype with motor 
impairment, shorter life span, iron accumulation and ferritin rich inclusion bodies in the brain and in 
different organs (Vidal et al. 2008). The in vivo (Vidal et al. 2008; Barbeito et al. 2009) and in vitro 
data (Cozzi et al. 2006; Baraibar et al. 2008) suggest that the mutant FtLs co-assemble with the 
endogenous ferritin and affect both iron loading and iron release. This would lead to a vicious cycle 
in which the augmented free iron pool would stimulate the synthesis of endogenous ferritin; the lack 
of a proper chelating capacity of the polymer would result in increased ROS generation, 
intensification in protein ubiquitination, proteasomal dysfunction and accumulation of ferritin 
aggregates (Levi and Finazzi 2014). The disorder is the most compelling evidence that perturbation 
of ferritin function and iron homeostasis may lead to neurodegeneration. No mutation in the coding 
sequence of FtH are known, indirectly confirming that the absence of such protein is not compatible 
with life. Sequence variations in the IRE at the 5’UTR of ferritin L are associated with the 
Hereditary Hyperferritinemia Catarct Syndrome (OMIM600886), with elevated serum ferritin levels 
and early appearance of bilateral cataract (Beaumont et al. 1995). Numerous type of mutations have 
been identified; they all reduce the affinity of the IRE for IRPs, thus resulting in a constitutive over-
expression of the FtL protein. This seems to cause ferritin L precipitation in the lenses (Goralska et 
al. 2001; Kannengiesser et al. 2009), but no alterations of iron homeostasis, even though the FtL 
excess occurs in all tissues. Also FtL haploinsufficiency did not lead to any clinical manifestation or 
evident perturbation of iron homeostasis (Cremonesi et al. 2004) and one case with homozygous 
inactivation of FtL gene did not show evident problems in iron regulation but some neurological 
defects, such as idiopathic generalized seizures and atypical restless leg syndrome (Cozzi et al. 
2013). These data strongly indicate that FtL does not have a central role in the regulation of iron 
homeostasis.   
 
Ferritin in brain disorders with altered iron homeostasis. 
Iron is an abundant metal in the brain, mostly localized in the Substantia Nigra (SN) and in the 
basal ganglia, with concentrations similar to those of the liver. The amount of the metal increases 
with aging (Bartzokis et al. 1999; Zecca et al. 2005), but this is not necessarily linked to  
pathological alteration or dysfunction of the brain; a parallel increase of ferritins is actually 
observed in normal aging (Connor et al. 1995) that should guarantee the safe storage and handling 
of the metal. Local siderosis has been linked to different neurodegenerative disorders, including 
Alzheimer’s (AD) and Parkinson’s disease (PD); however its clinical relevance and its role in the 
pathogenesis are largely unraveled; on one hand iron accumulation could be associated to excess 
labile iron that could play a causative or exacerbating role in disease development by increasing 
ROS generation, on the other hand its deposition may be simply an epiphenomenon of cell death 
due to other unrelated causes. A direct relationship between total iron (in the plasma) and labile iron 
pool (in the cells) is evident in experimental or clinical systemic iron overload, where the benefits 
obtained with a cell-permeant iron chelator confirm the pathological relevance of non-ferritin bound 
iron (Pennell et al. 2011). Even though the generating mechanisms of brain siderosis are different, 
the same setting may be found in it, as suggested by the promising results obtained by targeting 
chelatable iron with deferiprone in an experimental model of PD and in early-stage PD patients 
(Devos et al. 2014). Important aspects in this possible pathogenic mechanisms are not clear yet; in 
particular, what is the difference between iron accumulation in normal ageing and in 
neurodegenerative disorders with brain iron overload? Is it just a matter of amount of iron or other 
mechanisms controlling iron balance are involved; if the IRP-dependent system controlling the 
intracellular iron homeostasis is efficient in the first condition, is it no more competent in the latter? 
Being cytosolic ferritin an important factor in determining intracellular LIP, its analysis may 
provide insight into this aspects. Ferritin is the main iron storage molecule also in the brain; 
immunohistochemistry (IHC) analysis show that it is abundant in oligodendrocytes, with both H 
and L chains, it is present in glial cells, where the L chain is predominant, and in neurons, mostly as 
H chain (Connor et al. 1994). In the whole brain the H chain is more abundant than the L one and 
both increase with age, in parallel to iron. Since ferritin levels are mainly controlled by iron 
availability, its measurement by IHC or western blotting is usually considered as a marker of the 
metal distribution in the brain parenchyma, useful to confirm MRI data eventually indicating 
perturbation in brain iron density. For example, imaging and transcranial sonography studies 
indicated reduced concentration of iron in the SN of patients with early onset of the Restless Legs 
Syndrome, but normal iron in those with late onset (Schmidauer et al. 2005; Earley et al. 2006). The 
histological analysis of the same brain region in autopsies of the first group showed a reduction of 
ferritin (particularly of the H chain) in melanized neurons, that paralleled the hypointense signal of 
MRI (Connor et al. 2003). Interestingly such reduction was accompanied by an increase of FtMt 
(Snyder et al. 2009). In most conditions, ferritin behaves as a dynamic storage, adjusting its level 
and expression according to the local abundance of iron and controlling LIP level. Whether this 
fluctuations and adjustments are always perfectly fit to the need and balance of the neural cells is 
difficult to know. Alteration in this dynamic equilibrium could be dangerous, giving rise to excess 
of free iron or, alternatively, to excess iron sequestration. Such an “iron imbalance” in the brain 
could have different origins, but the switch of ferritin from the protective storage role to a pro-
oxidant action has been observed in different in vitro and in vivo experimental settings (see above) 
and may be relevant in some pathological conditions. This is clearly suggested by the discovery that 
mutations in ferritin gene leads to Neuroferrintinopathy, a neurodegenerative disorder with brain 
iron accumulation. In particular, the study of in vitro and in vivo models of the disease have shown 
that the alteration of ferritin capacity to safely load and retain iron gives raise to excess free and 
redox-active iron, augmented oxidative damage, neuronal degeneration and death (Levi and Finazzi 
2014). Whether similar processes may take place in other forms of sporadic neurodegenerative 
disorders is not clear yet, even though some indication are present in the literature. In AD iron is 
particularly increased in the parietal cortex, motor cortex, and hippocampus (Zecca et al. 2004). 
Most of it co-localize with the A plaques. IHC and  transmission electron microscopy (TEM) 
analyses revealed that also ferritin intensively decorates the senile plaques and the surrounding glial 
cells (Lovell et al. 1998; Roberts et al. 2012). The overall increase in ferritin seems to exceed that of 
iron, at least in the hippocampus of AD patients, hence most iron should be ferritin-bound 
(Galazka-Friedman et al. 2004), thus in a safe state. Interestingly a quantitative analyses of 
isoferritins in the brain of controls and AD patients found region and disease specific alteration of 
the balance between H and L subunits, with the L subunit concentration being lower in the cortex 
and in the SN of AD brain (Connor et al. 1995); a proteomic analysis of AD hippocampi also found 
elevated H-chain levels (Sultana et al. 2007). As observed in different experimental systems, this 
imbalance could be associated with an abnormal iron management by ferritin itself. Possible 
support for this hypothesis came from the analysis of the composition of ferritin cores performed by 
analytical TEM (Quintana and Gutiérrez 2010): while ferrihydrite, with an hexagonal cell unit, was 
the major component of the mineral core in ferritin from non-pathological samples, mixed ferric 
and ferrous oxide, with a cubic cell unit, were found in ferritin from AD brains. Further work is 
required to support the speculative suggestion of differences in the biomineralization process 
catalyzed by ferritin in patients’ brains and their role in the development and/or progression of the 
neurodegenerative process.  PD is a neurodegenerative disorder characterized by the progressive 
death of neurons in the SN pars compacta, with accumulation of -synuclein, formation of Lewy 
bodies, intensive reactive gliosis and functional decay of the nigro-striatal circuitry (Zecca et al. 
2004). The hypothesis of an increase of iron in the SN of patients is generally accepted and 
documented (Sofic et al. 1988; Dexter et al. 1989; Oakley et al. 2007), even though the difference 
between controls and PD samples appears to be affected by factors such as disease severity, gender 
or  age of onset (Snyder and Connor 2009). Less clear are the modification of ferritin levels, with 
studies showing an increase (Sofic et al. 1988; Licker et al. 2014), a decrease (Dexter et al. 1990; 
Connor et al. 1995; Faucheux et al. 2002) or changes in the relative H/L ratio (Koziorowski et al. 
2007), with consequent functional implication for iron handling.  The loss of neurons (rich in H 
subunit), the reactive gliosis (microglial cells are rich in L ferritin) as well as technical aspects such 
as the type of antibodies applied for IHC may be important confounding factor in this analysis 
(Snyder and Connor 2009). Albeit adequate in total amount, ferritin may be defective in function, as 
suggested by the increased labile iron found in the SN of PD patients by atomic absorption 
(Wypijewska et al. 2010) and by the significant asymmetry of ferritin Moessabauer spectra in the 
same brain region from PD patients (Galazka-Friedman et al. 2004). When confirmed, this would 
suggest a possible loss of function of ferritin in the SN of patients. Perturbation of iron balance in 
the brain is also documented in prion diseases, a group of neurodegenerative disorders affecting 
humans (Crutzfeld Jacob disease), and animals (scrapie in sheep and goats, and chronic wasting 
disease in deer and elks) (Prusiner 1998). The main event in the pathogenesis of these disorders is 
the conformational change of the wild type prion protein (PrPC) to a pathological, b-sheet enriched 
form (PrPsc) (Prusiner 2013). The noxious activity of PrPsc is not defined yet. Interestingly mice 
lacking the gene showed signs of systemic iron deficiency (Singh et al. 2009b) and a progressive 
decrease of the metal is described in brains from affected patients or animals, despite an increase in 
total iron load (Singh et al. 2009a) together with loss of function of PrPC. There is evidence that 
PrPc could have ferroxidase activity and its absence could reduce iron uptake in diseased brain 
(Singh et al. 2013), but an important role could be attributed to the formation of aggregates between 
the PrPsc and iron-rich ferritin (Singh et al. 2012). The ferritin isolated form affected brains is 
insoluble and retains iron even when exposed to harsh denaturing conditions. These aggregates can 
exert a pro-oxidant activity and favor further accumulation of PrPsc and, in the long run, may lead 
to an iron-deficient phenotype with upregulation of TfR expression (Singh et al. 2014). Altogether 
these observation suggest that different factors (mutations, altered subunits ratio, interaction with 
other protein/molecules) may affect the ferritin capacity to properly modulate the dynamic 
sequestration and release of iron and induce a switch towards a pro-oxidant activity of the protein,  
possibly contributing to the development and/or progression of some neurodegenerative processes 
(figure 6). A possible involvement of ferritin in pathomechanisms of  neurodegeneration may be 
also linked to novel non-iron-related functions (see below). Interesting examples are the binding 
between FtH and CXCR4 (Li et al. 2006) and FtL and Pen2 (Li et al. 2013). In the first case the 
interaction results in a negative modulation of the CXCL12/CXCR4 pathway, which is known to 
regulate neuronal migration, differentiation and survival.  An (iron-dependent) increase in cytosolic 
ferritin could impinge on this signaling cascade and induce or accelerate the neural death. The 
interaction of FtL with Pen-2 seems to affect the -secretase activity and thus the processing of the 
Amyloid Precursor Protein (APP), resulting in an increased production of beta amyloid (A), the 
main component of senile plaques and central pathological factor in AD.  A direct relationship 
between iron level and A production has been recently observed also in a transgenic mouse model 
of AD, together with perturbation of the glutamatergic neurotransmission (Becerril-Ortega et al. 
2014). If one considers that iron levels regulates APP expression through an IRE in its mRNA 
(Rogers et al. 2002) and that APP itself may participate in  the ferroportin-dependent iron efflux 
from the cells acting as a ferroxidase (Duce et al. 2010), it is then possible that the capacity of 
ferritin to control iron homeostasis in neural cells may be central in the pathogenesis of AD. 
 
 
Mammalian cytosolic ferritin, not only iron. 
Recent data suggest possible binding partners for the cytosolic ferritin, not necessarily linked to its 
role in iron homeostasis and indicating alternative functions. Robust data suggest involvements in 
signal transduction pathways. A functional interaction with granulocyte colony-stimulating factor 
(G-CSF) was documented both in COS-7 cells overexpressing G-CSF receptor and FtH and in 
mouse bone-marrow hematopoietc cells (Yuan et al. 2004). The interaction involved the COOH-
terminus of the intracellular domain of G-CSF receptor. The treatment of the cells with G-CSF 
induced FtH dissociation after 30 min, accompanied by an increase of intracellular LIP and ROS 
formation and Stat3 phosphorylation, thus suggesting the existence of a G-CSF-FHC-LIP-ROS 
pathway in hematopoietic cells. It has been shown that FtH acts as a negative regulator of the 
chemokine receptor CXCR4 via direct interaction with its intracellular domain (Li et al. 2006). 
Stimulation of CXCR4 by its ligand CXCL12 induces FtH phosphorilation at serine 178 and 
subsequent translocation to the nucleus. The discovery that opioids induce new synthesis of  FtH 
can explain the heterologous desensitization observed between -opioid receptors (MOR) and 
CXCR4 in neurons (Sengupta et al. 2009), a possible mechanism underlining the neurological 
dysfunction and cerebral damage determined by opiates. This activity is independent of iron binding 
since it is maintained by a ferroxidase deficient FtH (Pitcher et al. 2014). Since CXCR4 is also a co-
receptor for HIV through gp120 and TAT proteins, it is possible that ferritin H induction represents 
the crossroad at which the signaling cascade of opiates and HIV meet to generate the deleterious 
cerebral effects often observed in HIV-positive opiate-abusers (figure 7). Indeed, drug abusers and 
HIV patients with neurological symptoms had increased levels of FtH (Pitcher et al.). Altogether the 
FtH-dependent deregulation of CXCL12/CXCR4 pathway seems to  contribute to the development 
of cognitive dysfunction in neuroAIDS (Pitcher et al. 2014). Since the CXCL12/CXCR4 signaling 
cascade has important roles in different cellular types and functions (Cojoc et al. 2013), it could be 
of interest to verify the relevance of this data in cells other than neurons. In rat liver ferritin H and L 
interact with apolipoprotein B (ApoB), block its secretion and enhance its intracellular degradation 
(Rashid et al. 2002; Hevi and Chuck 2003). This action seemed to be independent from the iron 
binding capacity (Hevi and Chuck 2003) and may be mediated by hemin. This molecular interaction 
could be relevant in the regulation of lipid transport and storage in the liver and potentially explain 
the steatosis associated with HCV infection. A recent study showed that the viral infection up-
regulated FtH expression at a transcriptional level, independent of iron or oxidative stress, and 
inhibited the secretion of ApoB-containing lipoprotein particles. This could be rescued by FtH 
downregulation with specific siRNA. Interestingly, the reduction in FtH content was also associated 
with a less robust viral infection, thus indicating that FtH may be a host factor required for HCV 
infection (Mancone et al. 2012). On the basis of the possible role of iron in the development of 
neurodegenerative processes, it is of particular interest a recent report showing that FtL can interact 
with Pen-2, a subunit of the multiprotein complex associated with the -secretase activity, involved 
in the processing of the amyloid precursor protein (Li et al. 2013).The interaction has been found by 
the yeast two hybrid system and co-immunoprecipitation of the two proteins in cells overexpressing 
them. FtL overexpression or its induction by iron resulted in Pen-2 stabilization and increased beta-
amyloid production due to stimulation of the -secretase activity.  Opposite results were obtained by 
turning down FtL expression by specific siRNA. Further studies are needed to confirm the 
physiological relevance of the data. A peptide corresponding to amino acids 19 to 125 of the human 
FtH has been shown to interact with surviving, an anti-apoptotic protein strongly expressed in 
different types of cancer cells (Weiss et al. 2012). The peptide, expressed as a fusion protein with a 
variant of the human thioredoxin protein, was able to target the anti-apoptotic function of survivin 
and cause tumor cell death. The full length FtH did not show the same binding activity in the yeast 
two hybrid system,  so it seems not probable that this can be a physiological interaction. 
 
Conclusions 
The ferritin molecule has been known for almost 80 years but new interesting aspects related both 
to iron homeostasis and other novel possible functions continue to emerge from its study. The 
strong relationship between iron and ROS generation puts ferritin in a cardinal position for the 
control of oxidative damage in the cells. The possibility that perturbation of the ferritin storage and 
antioxidant function could play a fundamental role in pathological processes associated with 
increased oxidative stress is of extreme interest, but, with the exception of the Neuroferritinopathy 
condition, it awaits for further experimental consolidation and analysis of the molecular mechanism 
involved in it; in this regard, and particularly for neurodegenerative processes,  also the relationship 
between  mitochondrial and cytosolic ferritin should be further explored. Cytosolic ferritin has been 
recently shown to interact with different protein partners and possibly to the participate to some 
specific, non-iron-related activities. In most cases the interaction has been attributed to a single 
ferritin chain, but in depth analyses of the interaction with the ferritin 24-mer is still lacking ad 
required to confirm the physiological relevance of the data. With this premises, we expect that the 
ferritin field will be of great interest for many years yet. 
 
Figures 2 and 4 have been adapted and/or reprinted from Biochimica et Biophysica Acta, 1800 
(2010) , F. Bou-Abdallah, The iron redox and hydrolysis chemistry of the ferritins, with permission 
from Elsevier. 
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